Key result
Shear gradient-activated microfluidic device tracks coagulation changes more reliably than standard clotting assays in pigs.
Accurate assessment of blood haemostasis is essential for the management of patients who use extracorporeal devices, receive anticoagulation therapy or experience coagulopathies. However, current monitoring devices do not measure effects of haemodynamic forces that contribute significantly to platelet function and thrombus formation. Here we describe a microfluidic device that mimics a network of stenosed arteriolar vessels, permitting evaluation of blood clotting within small sample volumes under pathophysiological flow. By applying a clotting time analysis based on a phenomenological mathematical model of thrombus formation, coagulation and platelet function can be accurately measured in vitro in patient blood samples. When the device is integrated into an extracorporeal circuit in pig endotoxemia or heparin therapy models, it produces real-time readouts of alterations in coagulation ex vivo that are more reliable than standard clotting assays. Thus, this disposable device may be useful for personalized diagnostics and for real-time surveillance of antithrombotic therapy in clinic.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2016) studied Coagulopathies and extracorporeal device use. Shear gradient-activated microfluidic device vs. Standard clotting assays was evaluated on Coagulation and platelet function readouts (in vitro and ex vivo). A shear gradient-activated microfluidic device produced real-time ex vivo readouts of coagulation alterations that were more reliable than standard clotting assays in pig models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: